A Phase 1, Open-Label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2010

At a glance

  • Drugs TRC 093 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2010 Final results presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
    • 09 Feb 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual patient number (19) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top